AN ECONOMIC EVALUATION OF CABOZANTINIB VS. EVEROLIMUS IN THE SECOND-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA

被引：0
|
作者：
Hart, L. A. [1 ]
Carlson, J. J. [1 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN135
引用
收藏
页码：A111 / A111
页数：1
相关论文
共 50 条
  • [31] Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
    Shi, Fenghao
    He, Zixuan
    Su, Hang
    Wang, Lin
    Han, Sheng
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [32] ECONOMIC EVALUATION OF EVEROLIMUS AS SECOND LINE TREATMENT IN METASTATIC RENAL CANCER IN MEXICO
    Nevarez-Sida, A.
    Fuentes-Alburo, A.
    VALUE IN HEALTH, 2012, 15 (04) : A221 - A221
  • [33] Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
    Geczi, Lajos
    Bodoky, Gyorgy
    Rokszin, Gyorgy
    Fabian, Ibolya
    Torday, Laszlo
    PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (04) : 2201 - 2207
  • [34] Comparing ITC results from lenvatinib plus everolimus for second-line treatment of advanced/metastatic renal cell carcinoma: Crossover versus no crossover
    Garib, S.
    Tremblay, G.
    Meier, G.
    McElroy, H.
    Guo, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [35] ECONOMIC EVALUATION OF AXITINIB FOR SECOND LINE TREATMENT IN ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA - THE PORTUGUESE CASE
    Miguel, L. S.
    Luz, R.
    VALUE IN HEALTH, 2014, 17 (07) : A639 - A640
  • [36] Cabopoint: a phase II study of second-line cabozantinib in patients with metastatic renal cell carcinoma (RCC)
    Ivanyi, P.
    Albiges, L.
    Schmidinger, M.
    Taguieva-Pioger, N.
    Perol, D.
    Gruenwald, V
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 274 - 274
  • [37] Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung
    Lu, Shun
    Li, Wei
    Zhou, Caicun
    Hu, Cheng-Ping
    Qin, Shukui
    Cheng, Gang
    Feng, Jifeng
    Wang, Jie
    Cseh, Agnieszka
    Peil, Barbara
    Gibson, Neil
    Ehrnrooth, Eva
    Zhang, Li
    ONCOTARGETS AND THERAPY, 2018, 11 : 8565 - 8573
  • [38] An in vitro comparison between Cabozantinib as first- and second-line agent in metastatic renal cell carcinoma
    Zaccagnino, A.
    Vynnytska-Myronovska, B.
    Stoeckle, M.
    Junker, K.
    EUROPEAN UROLOGY, 2021, 79 : S751 - S751
  • [39] Everolimus as second-line therapy for metastatic renal cell carcinoma: a 'real-life' study
    Rizzo, Mimma
    Facchini, Gaetano
    Savastano, Clementina
    Di Lorenzo, Giuseppe
    De Lucia, Luigi
    Maiorino, Luigi
    Casale, Beniamino
    Grimaldi, Giuseppe
    Formato, Roberta
    Febbraro, Antonio
    Carteni, Giacomo
    FUTURE ONCOLOGY, 2015, 11 (02) : 219 - 224
  • [40] CaboPoint: A phase II study of second-line cabozantinib in patients with metastatic renal cell carcinoma (RCC)
    Albiges, L.
    Schmidinger, M.
    Taguieva-Pioger, N.
    Perol, D.
    Gruenwald, V.
    ANNALS OF ONCOLOGY, 2020, 31 : S608 - S609
12345